Literature DB >> 19129986

Revertant somatic mosaicism in the Wiskott-Aldrich syndrome.

Brian R Davis1, Fabio Candotti.   

Abstract

Up to 11% of patients affected with Wiskott-Aldrich syndrome (WAS) have presented with somatic mosaicism due to spontaneous in vivo reversion to normal of the original mutation or second-site compensatory mutations that restored production of the WAS gene product. The reasons underlying the high prevalence of this phenomenon in WAS are unclear and may include strong selective advantage of revertant cells over mutated populations, abnormally high general mutation rate and/or increased susceptibility of specific WAS gene sequences to DNA polymerase errors. Additional studies in human samples and in vitro/in vivo models of the disease will likely yield further insights into the mechanisms responsible for the occurrence of revertant mosaicism in WAS and elucidate additional biological characteristics of the WAS gene and protein.

Entities:  

Mesh:

Year:  2009        PMID: 19129986     DOI: 10.1007/s12026-008-8091-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  23 in total

1.  Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells.

Authors:  V Stephan; V Wahn; F Le Deist; U Dirksen; B Broker; I Müller-Fleckenstein; G Horneff; H Schroten; A Fischer; G de Saint Basile
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

2.  Large granular lymphocyte proliferation and revertant mosaicism: two rare events in a Wiskott-Aldrich syndrome patient.

Authors:  Kaan Boztug; Ulrich Baumann; Matthias Ballmaier; David Webster; Inga Sandrock; Roland Jacobs; Thomas Lion; Sandra Preuner; Manuela Germeshausen; Gesine Hansen; Karl Welte; Christoph Klein
Journal:  Haematologica       Date:  2007-03       Impact factor: 9.941

Review 3.  The Wiskott-Aldrich syndrome: disordered actin dynamics in haematopoietic cells.

Authors:  A J Thrasher; S Burns; R Lorenzi; G E Jones
Journal:  Immunol Rev       Date:  2000-12       Impact factor: 12.988

4.  Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome.

Authors:  Maxim I Lutskiy; Diana S Beardsley; Fred S Rosen; Eileen Remold-O'Donnell
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

Review 5.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

6.  Multiple independent second-site mutations in two siblings with somatic mosaicism for Wiskott-Aldrich syndrome.

Authors:  K Boztug; M Germeshausen; I Avedillo Díez; V Gulacsy; J Diestelhorst; M Ballmaier; K Welte; L Maródi; Li Chernyshova; C Klein
Journal:  Clin Genet       Date:  2008-05-13       Impact factor: 4.438

7.  Self-induced correction of the genetic defect in tyrosinemia type I.

Authors:  E A Kvittingen; H Rootwelt; R Berger; P Brandtzaeg
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

8.  A second-site mutation in the initiation codon of WAS (WASP) results in expansion of subsets of lymphocytes in an Wiskott-Aldrich syndrome patient.

Authors:  Wei Du; Satoru Kumaki; Toru Uchiyama; Akihiro Yachie; Chung Yeng Looi; Shin Kawai; Masayoshi Minegishi; Narayanaswamy Ramesh; Raif S Geha; Yoji Sasahara; Shigeru Tsuchiya
Journal:  Hum Mutat       Date:  2006-04       Impact factor: 4.878

9.  The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2006.

Authors:  Donn M Stewart; Fabio Candotti; David L Nelson
Journal:  J Clin Immunol       Date:  2007-08-10       Impact factor: 8.317

10.  Evolution of highly polymorphic T cell populations in siblings with the Wiskott-Aldrich Syndrome.

Authors:  Maxim I Lutskiy; Jun Y Park; Susanna K Remold; Eileen Remold-O'Donnell
Journal:  PLoS One       Date:  2008-10-20       Impact factor: 3.240

View more
  20 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  Gene defects in the soma: some get it and some don't!

Authors:  Bernice Lo; Michael J Lenardo
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 3.  Selection and mutation in the "new" genetics: an emerging hypothesis.

Authors:  Bruce Gottlieb; Lenore K Beitel; Carlos Alvarado; Mark A Trifiro
Journal:  Hum Genet       Date:  2010-01-23       Impact factor: 4.132

4.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

5.  Platelets from WAS patients show an increased susceptibility to ex vivo phagocytosis.

Authors:  Amanda Prislovsky; Xueying Zeng; Robert A Sokolic; Elizabeth N Garabedian; Praveen Anur; Fabio Candotti; Ted S Strom
Journal:  Platelets       Date:  2012-07-19       Impact factor: 3.862

6.  Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.

Authors:  Alexander Astrakhan; Blythe D Sather; Byoung Y Ryu; Socheath Khim; Swati Singh; Stephanie Humblet-Baron; Hans D Ochs; Carol H Miao; David J Rawlings
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 7.  WASP: a key immunological multitasker.

Authors:  Adrian J Thrasher; Siobhan O Burns
Journal:  Nat Rev Immunol       Date:  2010-03       Impact factor: 53.106

Review 8.  Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment.

Authors:  Sung-Yun Pai; Luigi D Notarangelo
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

9.  Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10.

Authors:  Keith A Choate; Yin Lu; Jing Zhou; Murim Choi; Peter M Elias; Anita Farhi; Carol Nelson-Williams; Debra Crumrine; Mary L Williams; Amy J Nopper; Alanna Bree; Leonard M Milstone; Richard P Lifton
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

Review 10.  Recent Advances in DOCK8 Immunodeficiency Syndrome.

Authors:  Qian Zhang; Huie Jing; Helen C Su
Journal:  J Clin Immunol       Date:  2016-05-20       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.